1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
0000-0003-0475-438X
Zerbe, O.
Bardelli, M.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
Cell
1097-4172
171
229
241.e15
10.1016/j.cell.2017.09.002
28938115
A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential.
2017
10.2210/pdb5omz/pdb
pdb_00005omz
12479.393
Envelope Protein
DOMAIN DIII, UNP residues 585-699
1
man
polymer
no
no
MDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKM
MLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGK
MDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKM
MLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGK
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
ZIKV
sample
1
115
64320
Zika virus (strain Mr 766)
562
Escherichia coli
plasmid
Biological sequence
pET21a
pdbx_nmr_software
database_2
pdbx_database_status
pdbx_nmr_spectrometer
repository
Initial release
Data collection
Data collection
Database references
Other
1
0
2017-10-04
1
1
2019-05-08
1
2
2023-06-14
_pdbx_nmr_software.name
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_nmr_data
_pdbx_nmr_spectrometer.model
Solution structure of domain III (DIII)of Zika virus Envelope protein
N
PDBE
Y
PDBE
2017-08-02
REL
REL
REL
REL
structures with the lowest energy
100
20
isotropic
1
2D 1H-15N HSQC
isotropic
2
2D 1H-13C HSQC aliphatic
isotropic
2
2D 1H-13C HSQC aromatic
isotropic
2
3D HNCO
isotropic
2
3D HN(CA)CO
isotropic
2
3D CBCA(CO)NH
isotropic
2
3D HNCACB
isotropic
2
3D HCCH-TOCSY
isotropic
2
3D H(C)CH
isotropic
2
3D HBHA(CO)NH
isotropic
2
3D 1H-15N NOESY
isotropic
2
3D 1H-13C NOESY aliphatic
isotropic
2
3D 1H-13C NOESY aromatic
isotropic
2
2D 1H-15N HSQC
isotropic
2
3D 1H-15N NOESY
isotropic
2
3D HNCO
800
uM
15N,13C
20
mM
natural abundance
50
mM
natural abundance
400
uM
2H,13C,15N
20
mM
natural abundance
50
mM
natural abundance
440
uM
natural abundance
0.27
mM
conditions_1
6.0
pH
1
atm
300
K
further refinement in AMBER
simulated annealing
1
lowest energy
800 uM 15N,13C ZIKA Envelope DIII, 20 mM sodium phosphate, 50 mM sodium chloride, 90% H2O/10% D2O
sample for resonance assignment and structure determination
sample_H2O
90% H2O/10% D2O
solution
400 uM 2H,13C,15N ZIKA Envelope DIII, 20 mM sodium phosphate, 50 mM sodium chloride, 440 uM ZKA190 Fab, 90% H2O/10% D2O
perdeuterated 13C,15N sample
sample for mapping
90% H2O/10% D2O
solution
Bruker Biospin
processing
TopSpin
2.1
Keller and Wuthrich
chemical shift assignment
CARA
1.93
Guntert, Mumenthaler and Wuthrich
structure calculation
CYANA
3.97
600
Bruker
AV-4
700
Bruker
AVANCE
MET
1
n
1
MET
1
A
ASP
2
n
2
ASP
2
A
LYS
3
n
3
LYS
3
A
LEU
4
n
4
LEU
4
A
ARG
5
n
5
ARG
5
A
LEU
6
n
6
LEU
6
A
LYS
7
n
7
LYS
7
A
GLY
8
n
8
GLY
8
A
VAL
9
n
9
VAL
9
A
SER
10
n
10
SER
10
A
TYR
11
n
11
TYR
11
A
SER
12
n
12
SER
12
A
LEU
13
n
13
LEU
13
A
CYS
14
n
14
CYS
14
A
THR
15
n
15
THR
15
A
ALA
16
n
16
ALA
16
A
ALA
17
n
17
ALA
17
A
PHE
18
n
18
PHE
18
A
THR
19
n
19
THR
19
A
PHE
20
n
20
PHE
20
A
THR
21
n
21
THR
21
A
LYS
22
n
22
LYS
22
A
ILE
23
n
23
ILE
23
A
PRO
24
n
24
PRO
24
A
ALA
25
n
25
ALA
25
A
GLU
26
n
26
GLU
26
A
THR
27
n
27
THR
27
A
LEU
28
n
28
LEU
28
A
HIS
29
n
29
HIS
29
A
GLY
30
n
30
GLY
30
A
THR
31
n
31
THR
31
A
VAL
32
n
32
VAL
32
A
THR
33
n
33
THR
33
A
VAL
34
n
34
VAL
34
A
GLU
35
n
35
GLU
35
A
VAL
36
n
36
VAL
36
A
GLN
37
n
37
GLN
37
A
TYR
38
n
38
TYR
38
A
ALA
39
n
39
ALA
39
A
GLY
40
n
40
GLY
40
A
THR
41
n
41
THR
41
A
ASP
42
n
42
ASP
42
A
GLY
43
n
43
GLY
43
A
PRO
44
n
44
PRO
44
A
CYS
45
n
45
CYS
45
A
LYS
46
n
46
LYS
46
A
VAL
47
n
47
VAL
47
A
PRO
48
n
48
PRO
48
A
ALA
49
n
49
ALA
49
A
GLN
50
n
50
GLN
50
A
MET
51
n
51
MET
51
A
ALA
52
n
52
ALA
52
A
VAL
53
n
53
VAL
53
A
ASP
54
n
54
ASP
54
A
MET
55
n
55
MET
55
A
GLN
56
n
56
GLN
56
A
THR
57
n
57
THR
57
A
LEU
58
n
58
LEU
58
A
THR
59
n
59
THR
59
A
PRO
60
n
60
PRO
60
A
VAL
61
n
61
VAL
61
A
GLY
62
n
62
GLY
62
A
ARG
63
n
63
ARG
63
A
LEU
64
n
64
LEU
64
A
ILE
65
n
65
ILE
65
A
THR
66
n
66
THR
66
A
ALA
67
n
67
ALA
67
A
ASN
68
n
68
ASN
68
A
PRO
69
n
69
PRO
69
A
VAL
70
n
70
VAL
70
A
ILE
71
n
71
ILE
71
A
THR
72
n
72
THR
72
A
GLU
73
n
73
GLU
73
A
SER
74
n
74
SER
74
A
THR
75
n
75
THR
75
A
GLU
76
n
76
GLU
76
A
ASN
77
n
77
ASN
77
A
SER
78
n
78
SER
78
A
LYS
79
n
79
LYS
79
A
MET
80
n
80
MET
80
A
MET
81
n
81
MET
81
A
LEU
82
n
82
LEU
82
A
GLU
83
n
83
GLU
83
A
LEU
84
n
84
LEU
84
A
ASP
85
n
85
ASP
85
A
PRO
86
n
86
PRO
86
A
PRO
87
n
87
PRO
87
A
PHE
88
n
88
PHE
88
A
GLY
89
n
89
GLY
89
A
ASP
90
n
90
ASP
90
A
SER
91
n
91
SER
91
A
TYR
92
n
92
TYR
92
A
ILE
93
n
93
ILE
93
A
VAL
94
n
94
VAL
94
A
ILE
95
n
95
ILE
95
A
GLY
96
n
96
GLY
96
A
VAL
97
n
97
VAL
97
A
GLY
98
n
98
GLY
98
A
GLU
99
n
99
GLU
99
A
LYS
100
n
100
LYS
100
A
LYS
101
n
101
LYS
101
A
ILE
102
n
102
ILE
102
A
THR
103
n
103
THR
103
A
HIS
104
n
104
HIS
104
A
HIS
105
n
105
HIS
105
A
TRP
106
n
106
TRP
106
A
HIS
107
n
107
HIS
107
A
ARG
108
n
108
ARG
108
A
SER
109
n
109
SER
109
A
GLY
110
n
110
GLY
110
A
SER
111
n
111
SER
111
A
THR
112
n
112
THR
112
A
ILE
113
n
113
ILE
113
A
GLY
114
n
114
GLY
114
A
LYS
115
n
115
LYS
115
A
author_and_software_defined_assembly
PISA
1
monomeric
light scattering
gel filtration
0
0
9230
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
THR
21
A
N
THR
21
A
O
GLU
35
A
O
GLU
35
A
O
ARG
63
A
O
ARG
63
A
N
ASP
85
A
N
ASP
85
A
N
ILE
95
A
N
ILE
95
A
O
ILE
102
A
O
ILE
102
1
A
SER
10
-176.15
112.65
1
A
ASN
68
-170.57
73.22
1
A
THR
75
-53.46
171.98
1
A
PRO
87
-69.79
-179.08
1
A
LYS
100
-94.67
34.62
2
A
ALA
39
-95.27
42.24
2
A
ASP
42
-96.22
35.69
2
A
ALA
52
-176.66
121.79
2
A
PRO
60
-69.79
87.89
2
A
ASN
68
-175.42
72.33
2
A
GLU
76
-59.98
179.25
2
A
PRO
87
-69.72
-172.22
2
A
LYS
100
-95.66
34.39
2
A
HIS
104
-163.68
114.82
3
A
ALA
39
-96.90
38.78
3
A
ASP
42
-173.74
107.83
3
A
ALA
52
-171.85
106.99
3
A
GLU
76
-54.51
172.37
3
A
PRO
87
-69.77
-173.22
3
A
LYS
100
-95.04
34.59
3
A
SER
109
-171.52
-179.09
3
A
ILE
113
-66.42
-175.84
4
A
SER
10
-94.98
41.57
4
A
THR
15
-151.47
82.60
4
A
ALA
16
-62.85
-176.95
4
A
ALA
39
-96.96
-68.59
4
A
ASN
68
-178.94
71.85
4
A
GLU
76
-59.34
178.37
4
A
PRO
87
-69.72
-173.88
4
A
LYS
100
-95.78
34.22
4
A
THR
112
-126.29
-57.81
5
A
LYS
7
-62.51
-70.64
5
A
THR
41
-131.26
-39.80
5
A
ASP
42
-161.51
101.52
5
A
PRO
87
-69.70
-170.79
5
A
LYS
100
-95.38
34.37
5
A
HIS
105
-53.51
102.29
6
A
ALA
25
-178.07
127.62
6
A
THR
41
-95.19
34.27
6
A
ASN
77
60.98
71.41
6
A
PRO
87
-69.72
-171.39
6
A
LYS
100
-94.61
35.13
6
A
LYS
101
-49.94
166.37
6
A
THR
112
-108.98
-73.54
7
A
ALA
52
-173.16
-178.77
7
A
PRO
60
-69.80
92.12
7
A
ASN
68
-174.06
73.40
7
A
THR
75
-53.32
172.36
7
A
LYS
100
-95.97
34.24
8
A
LYS
3
-169.38
114.16
8
A
GLN
50
-171.20
147.78
8
A
ASN
68
-172.55
74.02
8
A
LYS
100
-95.76
34.30
8
A
SER
109
-170.09
-177.95
9
A
SER
10
-171.04
121.73
9
A
ALA
16
-170.42
134.97
9
A
ALA
39
-101.46
71.30
9
A
ASN
68
-176.52
72.50
9
A
MET
80
-160.48
117.95
9
A
PRO
87
-69.75
-171.91
9
A
SER
109
-109.14
-63.75
9
A
THR
112
-105.22
44.23
10
A
ASP
2
-115.23
52.59
10
A
ALA
25
-172.75
129.75
10
A
ALA
39
-95.81
52.16
10
A
ASP
42
-160.19
98.09
10
A
ASN
68
-178.83
69.05
10
A
GLU
76
-63.44
-179.11
10
A
PRO
87
-69.74
-171.54
10
A
LYS
100
-95.25
34.39
10
A
SER
109
-137.55
-59.99
10
A
THR
112
-109.24
40.46
11
A
LYS
7
-60.70
-178.09
11
A
SER
10
-175.05
134.57
11
A
ALA
25
-178.25
124.08
11
A
THR
41
-95.51
35.78
11
A
ASP
42
-120.16
-67.50
11
A
ALA
52
-175.41
147.82
11
A
ASN
68
-175.90
68.46
11
A
GLU
76
-57.12
176.28
11
A
PRO
87
-69.76
-172.23
11
A
LYS
100
-94.91
34.55
12
A
ALA
25
-172.67
142.96
12
A
GLN
50
-173.93
143.51
12
A
THR
66
-54.76
174.16
12
A
ASN
68
-176.94
73.74
12
A
MET
80
-173.66
123.32
12
A
PRO
87
-69.76
-170.90
12
A
HIS
104
-164.78
116.54
13
A
LEU
4
-117.22
62.50
13
A
SER
12
-174.04
-178.76
13
A
THR
41
-95.22
34.91
13
A
ALA
52
-169.98
100.51
13
A
ASN
68
-165.08
73.74
13
A
THR
75
-53.01
171.77
13
A
PRO
87
-69.78
-170.92
13
A
LYS
100
-95.41
34.35
14
A
ALA
25
-171.14
119.78
14
A
ALA
39
-115.64
56.98
14
A
THR
41
-98.26
43.15
14
A
ASP
42
-108.45
42.53
14
A
ALA
52
-167.65
118.94
14
A
THR
66
-56.84
174.11
14
A
ASN
68
-179.05
73.62
14
A
PRO
87
-69.75
-171.32
14
A
LYS
100
-95.37
34.50
15
A
ALA
16
-63.00
-177.63
15
A
ASP
42
62.29
61.44
15
A
THR
66
-55.49
174.61
15
A
ASN
68
-167.19
74.26
15
A
GLU
76
-58.68
-177.34
15
A
PRO
87
-69.73
-170.84
15
A
SER
91
-131.09
-75.04
15
A
LYS
100
-94.53
34.57
16
A
THR
15
-151.03
80.70
16
A
ALA
39
-78.24
-75.71
16
A
PRO
60
-69.76
99.24
16
A
THR
75
-59.67
176.64
16
A
MET
80
-169.10
118.81
16
A
PRO
87
-69.66
-170.86
16
A
LYS
100
-95.91
34.34
17
A
PRO
60
-69.80
96.82
17
A
ASN
68
-175.40
73.33
17
A
PRO
87
-69.74
-175.05
17
A
LYS
100
-95.62
34.37
18
A
ALA
39
-96.64
41.94
18
A
THR
41
-54.04
-70.87
18
A
ASP
42
-161.92
102.94
18
A
LEU
64
-116.49
69.72
18
A
ILE
65
-121.01
-59.02
18
A
GLU
76
-58.86
-179.49
18
A
PRO
87
-69.76
-177.53
18
A
PHE
88
-52.12
103.55
18
A
SER
91
-93.77
-74.80
18
A
LYS
100
-94.39
34.69
19
A
ASP
2
-57.12
175.25
19
A
ASN
68
-153.81
73.44
19
A
THR
75
-56.82
178.43
19
A
PRO
87
-69.74
-171.36
19
A
LYS
100
-94.33
34.42
20
A
ALA
16
-57.52
174.84
20
A
ALA
25
-173.12
125.14
20
A
ALA
52
-174.61
144.48
20
A
ASN
68
-176.08
73.00
20
A
GLU
76
-59.16
175.64
20
A
PRO
87
-69.74
-177.02
20
A
LYS
100
-93.78
35.38
20
A
LYS
101
-49.41
165.83
N
Solution structure of domain III (DIII)of Zika virus Envelope protein
1
N
N
VIRAL PROTEIN
ZIKA virus Envelope protein domain, VIRAL PROTEIN, ZIKV
A
GLY
43
A
GLY
43
1
A
PRO
44
A
PRO
44
0.12
A
GLY
43
A
GLY
43
2
A
PRO
44
A
PRO
44
0.02
A
GLY
43
A
GLY
43
3
A
PRO
44
A
PRO
44
0.01
A
GLY
43
A
GLY
43
4
A
PRO
44
A
PRO
44
-0.02
A
GLY
43
A
GLY
43
5
A
PRO
44
A
PRO
44
0.12
A
GLY
43
A
GLY
43
6
A
PRO
44
A
PRO
44
0.03
A
GLY
43
A
GLY
43
7
A
PRO
44
A
PRO
44
-0.04
A
GLY
43
A
GLY
43
8
A
PRO
44
A
PRO
44
0.09
A
GLY
43
A
GLY
43
9
A
PRO
44
A
PRO
44
0.14
A
GLY
43
A
GLY
43
10
A
PRO
44
A
PRO
44
0.04
A
GLY
43
A
GLY
43
11
A
PRO
44
A
PRO
44
-0.06
A
GLY
43
A
GLY
43
12
A
PRO
44
A
PRO
44
0.02
A
GLY
43
A
GLY
43
13
A
PRO
44
A
PRO
44
0.02
A
GLY
43
A
GLY
43
14
A
PRO
44
A
PRO
44
0.08
A
GLY
43
A
GLY
43
15
A
PRO
44
A
PRO
44
0.16
A
GLY
43
A
GLY
43
16
A
PRO
44
A
PRO
44
0.12
A
GLY
43
A
GLY
43
17
A
PRO
44
A
PRO
44
-0.16
A
GLY
43
A
GLY
43
18
A
PRO
44
A
PRO
44
0.00
A
GLY
43
A
GLY
43
19
A
PRO
44
A
PRO
44
-0.08
A
GLY
43
A
GLY
43
20
A
PRO
44
A
PRO
44
0.11
A0A1V0E2E5_ZIKV
UNP
1
585
A0A1V0E2E5
MDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKM
MLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGK
585
699
5OMZ
1
115
A0A1V0E2E5
A
1
1
115
2
2
2
anti-parallel
anti-parallel
anti-parallel
A
PHE
20
A
PHE
20
A
LYS
22
A
LYS
22
A
GLU
35
A
GLU
35
A
VAL
36
A
VAL
36
A
ARG
63
A
ARG
63
A
LEU
64
A
LEU
64
A
LEU
84
A
LEU
84
A
ASP
85
A
ASP
85
A
VAL
94
A
VAL
94
A
ILE
95
A
ILE
95
A
ILE
102
A
ILE
102
A
THR
103
A
THR
103